Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Abstract: A unit container for a treatment fluid comprises a sealed enclosure of which one wall section thereof is formed with at least one opening. The enclosure is pressuriseable to discharge its contents thorough the opening or openings, which is or are of sufficient diameter to enable the generation of a jet and/or discrete droplets of treatment fluid discharged therefrom. The one wall section is typically a flat section of the enclosure wall, and the enclosure is typically a blister pack, with the wall section at a planar base of the blister. However the one wall section may be dome-shaped and formed with at least one opening in the top region of the dome. Containers of the invention may be provided in packages, for example in strip form or in planar arrays. Dispensing devices are described for discharging their content in treatment.

Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Abstract: A unit container for a treatment fluid comprises a sealed enclosure of which one wall section thereof is formed with at least one opening. The enclosure is pressuriseable to discharge its contents through the opening or openings, which is or are of sufficient diameter to enable the generation of a jet and/or discrete droplets of treatment fluid discharged therefrom. The one wall section is typically a flat section of the enclosure wall, and the enclosure is typically a blister pack, with the wall section at a planar base of the blister. However, the one wall section may be dome-shaped and formed with at least one opening in the top region of the dome. Containers of the invention may be provided in packages, for example in strip form or in planar arrays. Dispensing devices are described for discharging their contents in treatment.

Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Abstract: The present invention relates to a method for treating a patient suffering from a mental disorder, comprising administering to the patient an effective 5-HT1A agonistic and 5-HT2 antagonistic amount of a compound having the formula (I): or a pharmacologically active salt thereof.

Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Abstract: The present invention concerns compounds of the formula (I) ##STR1## wherein Ar are the same or different and are a phenyl group, optionally substituted with fluorine, or a pyrid-4-yl group, R.sub.1 and R.sub.2 are the same or different and are selected from hydrogen or lower alkyl, n is 2 or 3, X is nitrogen or methine and A is pyrimid-2-yl or a substituted or unsubstituted pyridyl group. The compounds are useful for treating mental disorders.

Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Abstract: Compounds of general formula (I) are useful for treating mental disorders, wherein R.sub.1 and R.sub.2 are the same or different and selected from hydrogen or lower alkyl; Ar are the same or different and selected from pyridyl and phenyl groups, n is 1 or 2, X is nitrogen or methine. When X is nitrogen, Y is methylene. When X is methine, Y is selected from nitrogen or oxygen. A is selected from carboxylic derivatives. The pharmacologically active salts of formula (I) are also embraced.

Abstract: A monoclonal antibody that reacts with the CA-242 antigen is provided. The antibody can be obtained by culturing the hybridoma cell line C242:II with the ECACC identification number 90012601, or an artificial or spontaneous mutant thereof. Cell lines producing the antibody are also provided. The antibody is useful for therapeutic and diagnostic purposes.

Abstract: A method for manufacturing an injectable preparation of a pharmaceutically active agent suitable for storage in a dual-chamber injection cartridge. A dual chamber injection cartridge is provided, including: a barrel; a front chamber for a solid component; a rear chamber for a liquid component; a displaceable front piston separating the front and rear chambers; a closure sealing the front end of the barrel; and a constriction between the front and rear ends of the barrel. The constriction has a non-circular cross-section and an openable bypass connection permitting passage of liquid between the rear and front chambers. Prior to opening the bypass connection, the front piston is positioned between the constriction and the rear end of the barrel. The constriction resists displacement of the front piston in a direction of the front end of the barrel when the piston is in the vicinity of the constriction.

Abstract: IGF-1 is administered to a patient for the treatment or prevention of atrophy of the gut mucosa.

Abstract: A medicine dispensing device including a slotted housing, a front end, a rear end, at least one threaded portion in the vicinity of the rear end, a dosage ampoule fitting in the vicinity of the front end and a discharge conduit for connection with a discharge ampoule. A hollow screw-threaded device receives the ampoule therein. The screw-threaded device is received by the rear end of the housing. The screw-threaded device includes an exterior surface provided with a threaded surface engaging the at least one threaded portion for securing the ampoule within the housing. A medicine discharge and metering device for metering and discharging the contents of the ampoule is received within the screw-threaded device and is movable in a direction of a longitudinal axis thereof.

Abstract: A device for an injection apparatus, including a dual-chamber injection cartridge. The cartridge includes a front end, a rear end, a front opening in the vicinity of a front end of the cartridge, a front chamber located in the vicinity of the front opening and including a drug freeze-dried in the front chamber, a rear chamber including a liquid component, a movable wall separating the front chamber and the rear chamber, a bypass for transferring the liquid component between the front chamber and the rear chamber, and a rear piston. The cartridge is slidably arranged within a cylindrical sleeve substantially the same length as the cartridge. A stopper is located in the vicinity of the front opening of the cartridge. The stopper is directed rearwardly coaxially with the cartridge, wherein as the sleeve is displaced rearwardly after the freeze-drying of the drug, the stopper enters the front opening of the cartridge to sealingly close the cartridge.

Abstract: A process for preparing antibodies specific for an amino acid sequence which comprises immunizing a mammal with a fused protein comprising said amino acid sequence fused to an immunogenic IgG binding protein is disclosed.

Abstract: A pyridoxylated hemoglobin is prepared in a one-step, one-container process from red blood cells or essentially stroma-free hemoglobin by suspending the cells or hemoglobin in an aqueous medium, adding a chemical reducing agent and a pyridoxylating agent, and heating the reaction mixture obtained at a certain temperature for a certain time, while maintaining reducing conditions in the reaction medium.